Amatera

Executive Summary

Amatera is a French biotechnology company leveraging synthetic biology to engineer microbial systems for the sustainable and cost-effective production of complex biologic therapeutics. Founded in 2021 and based in Paris, the company focuses on next-generation biologics targeting oncology, immunology, and rare diseases. Its platform enables the design and manufacturing of novel proteins and enzymes that are difficult to produce using traditional methods, potentially reducing costs and improving patient access. By combining advances in synthetic biology with protein engineering, Amatera aims to address limitations in current biologic manufacturing and expand the therapeutic landscape. The company is privately held and has an estimated employee range of 50–200, indicating a growing operational capacity. Although no specific funding or valuation data is available, its presence in a curated biotech startup list suggests investor interest and platform-stage development. Amatera's approach is positioned to disrupt the biologics market by offering a scalable, green alternative to conventional mammalian cell culture systems, with implications for both drug development and industrial enzyme production.

Upcoming Catalysts (preview)

• Q4 2026First IND submission for a lead oncology candidate40% success
• H1 2027Series A financing round led by top-tier life sciences VCs60% success
• Q3 2026Strategic partnership with a major pharma company for platform access30% success